Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 45

recruiting
3 968
countries
28
conditions
2 103

3 294 trials match your criteria

Acute lymphocytic leukaemia+1

Recruiting

Study of olverembatinib with chemotherapy versus standard therapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

B-cell lymphoma recurrent+1

Recruiting

Study of drug combination therapy in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma using odronextamab, loncastuximab tesirine and rituximab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab

Adenocarcinoma pancreas+2

Recruiting

Study of 177Lu-FAP-2286 alone and with drug combinations for patients with advanced solid tumors including non-small cell lung cancer, breast cancer, and pancreatic cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Colitis ulcerative+1

Recruiting

Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn's disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Vedolizumab

Infertility male

Recruiting

Study of vaginal pentoxifylline gel PKB171 compared to placebo in couples with mild male infertility due to low sperm count or poor sperm movement

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Pentoxifylline

Acute myocardial infarction

Recruiting

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab

Colorectal cancer metastatic+1

Recruiting

Study of melphalan followed by trifluridine-tipiracil and bevacizumab combination versus trifluridine-tipiracil and bevacizumab in liver metastatic colorectal cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Irritable bowel syndrome

Recruiting

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide Hydrochloride

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.